Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 With Attention Deficit Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Males/females 13-17 years of age meeting DSM-IV criteria for a primary diagnosis of ADHD~Exclusion Criteria:~* Controlled or uncontrolled comorbid psychiatric diagnosis (except ODD) with significant symptoms such as PTSD, psychosis, bipolar disease, severe OCD~* Known non-responder to stimulant medication~* Documented allergy or intolerance to ADDERALL, ADDERALL XR or amphetamines~* Conduct Disorder, hypertension, history of seizure~* Tic disorder or Tourette's disorder

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Adderall XR (10 mg) (Type: EXPERIMENTAL): None
- Adderall XR (20 mg) (Type: EXPERIMENTAL): None
- Adderall XR (30 mg) (Type: EXPERIMENTAL): None
- Adderall XR (40 mg) (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).